XORTX closes acquisition of Vectus kidney anti-fibrotic asset for US$3 million
PUBT · 04/13 21:00
Share
Listen to the news
- XORTX closed acquisition of Vectus Biosystems’ kidney anti-fibrotic program centered on pre-IND compound VB4-P5.
- Deal value set at USD 3 million, paid with 154,544 common shares plus 692,150 pre-funded warrants.
- Acquired package includes intellectual property, regulatory documentation, manufacturing data, and a patent family covering VB4-P5 use in kidney fibrosis.
- XORTX positioned VB4-P5 as a potential treatment for mid-to-late stage chronic kidney disease, targeting fibrosis and disease progression.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XORTX Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604131700PRIMZONEFULLFEED9688877) on April 13, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved